Editorial: Liraglutide and cardiometabolic effects: More than just another antiobesity drug?

Current Vascular Pharmacology

Volumn 14, Issue 1, 2016, Pages 76-79

  Katsiki, Niki ^a   Christou, Georgios A ^b   Kiortsis, Dimitrios N ^b  

^a ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

^b UNIVERSITY OF IOANNINA   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

ADIPONECTIN; ANTIOBESITY AGENT; C REACTIVE PROTEIN; FIBRINOGEN; GHRELIN; GLYCOSYLATED HEMOGLOBIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; LIRAGLUTIDE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PLASMINOGEN ACTIVATOR INHIBITOR 1; ANTIDIABETIC AGENT; GLUCAGON LIKE PEPTIDE 1;

BODY MASS; CARDIOMETABOLIC RISK; CARDIOVASCULAR DISEASE; CARDIOVASCULAR PARAMETERS; CHOLESTEROL BLOOD LEVEL; DIASTOLIC BLOOD PRESSURE; DRUG ACTIVITY; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; EDITORIAL; GLUCOSE METABOLISM; GLUCOSE TOLERANCE; HUMAN; IMPAIRED GLUCOSE TOLERANCE; METABOLIC SYNDROME X; METABOLISM PARAMETERS; MICROALBUMINURIA; NONALCOHOLIC FATTY LIVER; OBESITY; RANDOMIZED CONTROLLED TRIAL (TOPIC); RESTING HEART RATE; SYSTOLIC BLOOD PRESSURE; TREATMENT OUTCOME; TRIACYLGLYCEROL BLOOD LEVEL; WAIST CIRCUMFERENCE; WEIGHT REDUCTION; ANALOGS AND DERIVATIVES; FEMALE; MALE;

FEMALE; GLUCAGON-LIKE PEPTIDE 1; HUMANS; HYPOGLYCEMIC AGENTS; MALE; OBESITY;

EID: 84949843720     PISSN: 15701611     EISSN: 18756212     Source Type: Journal    
DOI: 10.2174/157016111401151126161741     Document Type: Editorial

References (59)

1. Christou GA, Katsiki N, Kiortsis DN. The current role of liraglutide in the pharmacotherapy of obesity. Curr Vasc Pharmacol 2015 Jun 15. [Epub ahead of print]
2. Pi-Sunyer X, Astrup A, Fujioka K, et al. SCALE Obesity and PrediabetesNN8022-1839 Study Group. A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management. N Engl J Med 2015; 373: 11-22.
3. American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care 2010; 33: S62-9.
4. Kong F, Chen YF, Jin K. A bias correction in testing treatment efficacy under informative dropout in clinical trials. J Biopharm Stat 2009; 19: 980-1000.
5. Mikhailidis DP, Elisaf M, Rizzo M, et al. “European panel on low density lipoprotein (LDL) subclasses”: a statement on the pathophysiology, atherogenicity and clinical significance of LDL subclasses: executive summary. Curr Vasc Pharmacol 2011; 9: 531-2.
6. Mikhailidis DP, Elisaf M, Rizzo M, et al. “European panel on low density lipoprotein (LDL) subclasses”: a statement on the pathophysiology, atherogenicity and clinical significance of LDL subclasses. Curr Vasc Pharmacol 2011; 9: 533-71.
7. Nikolic D, Katsiki N, Montalto G, et al. Lipoprotein subfractions in metabolic syndrome and obesity: clinical significance and therapeutic approaches. Nutrients 2013; 5: 928-48.
8. Ariel D, Kim SH, Abbasi F, et al. Effect of liraglutide administration and a calorie-restricted diet on lipoprotein profile in overweight/obese persons with prediabetes. Nutr Metab Cardiovasc Dis 2014; 24: 1317-22.
9. Stefanutti C, Labbadia G, Athyros VG. Hypertriglyceridaemia, postprandial lipaemia and non-HDL cholesterol. Curr Pharm Des 2014; 20: 6238-48.
10. Kolovou GD, Mikhailidis DP, Kovar J, et al. Assessment and clinical relevance of non-fasting and postprandial triglycerides: an expert panel statement. Curr Vasc Pharmacol 2011; 9: 258-70.
11. Voukali M, Kastrinelli I, Stragalinou S, et al. Study of postprandial lipaemia in type 2 diabetes mellitus: exenatide versus liraglutide. J Diabetes Res 2014; 2014: 304032.
12. Hermansen K, Bækdal TA, Düring M, et al. Liraglutide suppresses postprandial triglyceride and apolipoprotein B48 elevations after a fat-rich meal in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled, cross-over trial. Diabetes Obes Metab 2013; 15: 1040-8.
13. Katsiki N, Athyros VG, Karagiannis A, Mikhailidis DP. Characteristics other than the diagnostic criteria associated with metabolic syndrome: an overview. Curr Vasc Pharmacol. 2014; 12: 627-41.
14. Katsiki N, Athyros VG, Karagiannis A, Mikhailidis DP. Metabolic syndrome and non-cardiac vascular diseases: an update from human studies. Curr Pharm Des 2014; 20: 4944-52.
15. Alberti KG, Eckel RH, Grundy SM, et al. International Diabetes Federation Task Force on Epidemiology and Prevention; Hational Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; International Association for the Study of Obesity. Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation 2009; 120: 1640-5.
16. Athyros VG, Tziomalos K, Katsiki N, Doumas M, Karagiannis A, Mikhailidis DP. Cardiovascular risk across the histological spectrum and the clinical manifestations of non-alcoholic fatty liver disease: An update. World J Gastroenterol 2015; 21: 6820-34.
17. Athyros VG, Katsiki N, Karagiannis A. Nonalcoholic fatty liver disease and severity of cardiovascular disease manifestations. Angiology 2013; 64: 572-5.
18. Katsiki N, Athyros VG, Karagiannis A, Wierzbicki AS, Mikhailidis DP. Should we expand the concept of coronary heart disease equivalents? Curr Opin Cardiol 2014; 29: 389-95.
19. Lioudaki E, Ganotakis ES, Mikhailidis DP. Liver enzymes: potential cardiovascular risk markers? Curr Pharm Des 2011; 17: 3632-43.
20. Athyros VG, Katsiki N, Karagiannis A, Mikhailidis DP. Are statins ‘IDEAL’ for non-alcoholic fatty liver disease? Curr Med Res Opin 2014; 30: 229-31.
21. Athyros VG, Katsiki N, Karagiannis A, Mikhailidis DP. Statins and nonalcoholic fatty liver disease: a bright future? Expert Opin Investig Drugs 2013; 22: 1089-93.
22. Katsiki N, Athyros VG, Karagiannis A, Mikhailidis DP. The role of statins in the treatment of type 2 diabetes mellitus: an update. Curr Pharm Des 2014; 20: 3665-74.
23. Eguchi Y, Kitajima Y, Hyogo H, et al. Japan Study Group for NAFLD (JSG-NAFLD). Pilot study of liraglutide effects in non-alcoholic steatohepatitis and non-alcoholic fatty liver disease with glucose intolerance in Japanese patients (LEAN-J). Hepatol Res 2015; 45: 269-78.
24. Armstrong MJ, Houlihan DD, Rowe IA, et al. Safety and efficacy of liraglutide in patients with type 2 diabetes and elevated liver enzymes: individual patient data meta-analysis of the LEAD program. Aliment Pharmacol Ther 2013; 37: 234-42.
25. Olaywi M, Bhatia T, Anand S, Singhal S. Novel anti-diabetic agents in non-alcoholic fatty liver disease: a mini-review. Hepatobiliary Pancreat Dis Int 2013; 12: 584-8.
26. Katsiki N, Karagiannis A, Athyros VG, Mikhailidis DP. Hyperuricaemia: more than just a cause of gout? J Cardiovasc Med (Hagerstown) 2013; 14: 397-402.
27. Rizzo M, Obradovic M, Labudovic-Borovic M, et al. Uric acid metabolism in pre-hypertension and the metabolic syndrome. Curr Vasc Pharmacol. 2014; 12: 572-85.
28. Alani H, Tamimi A, Tamimi N. Cardiovascular co-morbidity in chronic kidney disease: Current knowledge and future research needs. World J Nephrol 2014; 3: 156-68.
29. Athyros VG, Katsiki N, Karagiannis A, Mikhailidis DP. Editorial: should chronic kidney disease be considered as a coronary heart disease equivalent? Curr Vasc Pharmacol 2012; 10: 374-7.
30. Athyros VG, Katsiki N, Karagiannis A, Mikhailidis DP. Stage of chronic kidney disease and severity of coronary heart disease manifestation. Expert Opin Pharmacother 2012; 13: 457-60.
31. Pai MP. Estimating the glomerular filtration rate in obese adult patients for drug dosing. Adv Chronic Kidney Dis 2010; 17: e53-e62.
32. Athyros VG, Mikhailidis DP. Pharmacotherapy: statins and new-onset diabetes mellitus--a matter for debate. Nat Rev Endocrinol 2012; 8: 133-4.
33. Katsiki N, Rizzo M, Mikhailidis DP, Mantzoros CS. New-onset diabetes and statins: throw the bath water out, but, please, keep the baby! Metabolism 2015; 64: 471-5.
34. Zafrir B, Jain M. Lipid-lowering therapies, glucose control and incident diabetes: evidence, mechanisms and clinical implications. Cardiovasc Drugs Ther 2014; 28: 361-77.
35. Pyke C, Heller RS, Kirk RK, et al. GLP-1 receptor localization in monkey and human tissue: novel distribution revealed with extensively validated monoclonal antibody. Endocrinology 2014; 155: 1280-90.
36. Giannoglou GD, Chatzizisis YS, Zamboulis C, Parcharidis GE, Mikhailidis DP, Louridas GE. Elevated heart rate and atherosclerosis: an overview of the pathogenetic mechanisms. Int J Cardiol 2008; 126: 302-12.
37. Ho JE, Larson MG, Ghorbani A, et al. Long-term cardiovascular risks associated with an elevated heart rate: the Framingham Heart Study. J Am Heart Assoc 2014; 3: e000668.
38. Vaseghi M, Shivkumar K. The role of the autonomic nervous system in sudden cardiac death. Prog Cardiovasc Dis 2008; 50: 404-19.
39. Alfaris N, Minnick AM, Hopkins CM, Berkowitz RI, Wadden TA. Combination phentermine and topiramate extended release in the management of obesity. Expert Opin Pharmacother 2015; 16: 1263-74.
40. Kiortsis DN. A review of the metabolic effects of controlled-release Phentermine/Topiramate. Hormones (Athens) 2013; 12: 507-16.
41. Garvey WT, Ryan DH, Look M, et al. Two-year sustained weight loss and metabolic benefits with controlled-release phentermine/topiramate in obese and overweight adults (SEQUEL): a randomized, placebo-controlled, phase 3 extension study. Am J Clin Nutr 2012; 95: 297-308.
42. Christou GA, Kiortsis DN. The efficacy and safety of the naltrexone/bupropion combination for the treatment of obesity: an update. Hormones (Athens) 2015; 14: 370-5.
43. Katsiki N, Hatzitolios AI, Mikhailidis DP. Naltrexone sustained-release (SR) + bupropion SR combination therapy for the treatment of obesity: ‘a new kid on the block’? Ann Med 2011; 43: 249-58.
44. Filippatos TD, Kiortsis DN, Liberopoulos EN, Mikhailidis DP, Elisaf MS. A review of the metabolic effects of sibutramine. Curr Med Res Opin 2005; 21: 457-68.
45. James WP, Caterson ID, Coutinho W, et al. SCOUT Investigators. Effect of sibutramine on cardiovascular outcomes in overweight and obese subjects. N Engl J Med 2010; 363: 905-17.
46. Chan EW, He Y, Chui CS, Wong AY, Lau WC, Wong IC. Efficacy and safety of lorcaserin in obese adults: a meta-analysis of 1-year randomized controlled trials (RCTs) and narrative review on short-term RCTs. Obes Rev 2013; 14: 383-92.
47. Sharma AM, Golay A. Effect of orlistat-induced weight loss on blood pressure and heart rate in obese patients with hypertension. J Hypertens 2002; 20: 1873-8.
48. Kiortsis DN, Filippatos TD, Elisaf MS. The effects of orlistat on metabolic parameters and other cardiovascular risk factors. Diabetes Metab 2005; 31: 15-22.
49. Hartaigh B, Gaksch M, Kienreich K, et al. Associations of daytime, nighttime, and 24-hour heart rate with four distinct markers of inflammation in hypertensive patients: the Styrian Hypertension Study. J Clin Hypertens (Greenwich) 2014; 16: 856-61.
50. Robert SA, Rohana AG, Shah SA, Chinna K, Wan Mohamud WN, Kamaruddin NA. Improvement in binge eating in non-diabetic obese individuals after 3 months of treatment with liraglutide-A pilot study. Obes Res Clin Pract 2015; 9: 301-4.
51. Pinkney J. The role of ghrelin in metabolic regulation. Curr Opin Clin Nutr Metab Care 2014; 17: 497-502.
52. Katsiki N, Mikhailidis DP, Gotzamani-Psarrakou A, Yovos JG, Karamitsos D. Effect of various treatments on leptin, adiponectin, ghrelin and neuropeptide Y in patients with type 2 diabetes mellitus. Expert Opin Ther Targets. 2011; 15: 401-20.
53. Rizzo M, Abate N, Chandalia M, et al. Liraglutide reduces oxidative stress and restores heme oxygenase-1 and ghrelin levels in patients with type 2 diabetes: a prospective pilot study. J Clin Endocrinol Metab 2015; 100: 603-6.
54. Clements JN, Shealy KM. Liraglutide: An injectable option for the management of obesity. Ann Pharmacother 2015; 49(8): 938-44.
55. Fujioka K. Safety and tolerability of medications approved for chronic weight management. Obesity (Silver Spring) 2015; 23: S7-11.
56. Iepsen EW, Torekov SS, Holst JJ. Liraglutide for Type 2 diabetes and obesity: a 2015 update. Expert Rev Cardiovasc Ther 2015; 13: 753-67.
57. Ryan D, Acosta A. GLP-1 receptor agonists: Nonglycemic clinical effects inweight loss and beyond. Obesity (Silver Spring) 2015; 23: 1119-29.
58. Scott LJ. Liraglutide: a review of its use in the management of obesity. Drugs 2015; 75: 899-910.
59. Bray GA. Obesity: Liraglutide-another weapon in the war against obesity? Nat Rev Endocrinol 2015; 11: 569-70.